ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

MYGN Myriad Genetics Inc

19.43
0.21 (1.09%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Myriad Genetics Inc NASDAQ:MYGN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.21 1.09% 19.43 18.61 22.08 20.09 19.40 19.85 820,170 22:58:41

MYRIAD GENETICS SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline...

19/05/2018 3:50am

PR Newswire (US)


Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Myriad Genetics Charts.

NEW ORLEANS, May 18, 2018 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until June 19, 2018 to file lead plaintiff applications in a securities class action lawsuit against Myriad Genetics, Inc. (NasdaqGS: MYGN), if they purchased the Company's securities between August 13, 2014 through March 12, 2018, inclusive (the "Class Period").  This action is pending in the United States District Court for the District of Utah.

Get Help

Myriad investors should visit us at https://www.claimsfiler.com/cases/view-myriad-genetics-securities-litigation or call to speak to our claim center toll-free at (844) 367-9658.  

About the Lawsuit

Myriad Genetics and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. 

On March 12, 2018, the Company revealed that it received a subpoena from the Department of Health and Human Services, regarding "an investigation into possible false or otherwise improper claims submitted for payment under Medicare and Medicaid," specifically relating to the Company's hereditary cancer testing dating back to January 1, 2014 (less than four months after the Company launched its myRisk test in September 2013) to the date of the subpoena's issuance.

On this news, the price of Myriad's shares plummeted over 12.14%

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

 

Cision View original content:http://www.prnewswire.com/news-releases/myriad-genetics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-myriad-genetics-inc---mygn-300651020.html

SOURCE ClaimsFiler

Copyright 2018 PR Newswire

1 Year Myriad Genetics Chart

1 Year Myriad Genetics Chart

1 Month Myriad Genetics Chart

1 Month Myriad Genetics Chart

Your Recent History

Delayed Upgrade Clock